D ilated cardiomyopathy is a heart muscle disorder defined by the presence of a dilated and poorly functioning left ventricle in the absence of abnormal loading conditions (hypertension, valve disease) or ischaemic heart disease suYcient to cause global systolic impairment. A large number of cardiac and systemic diseases can cause systolic impairment and left ventricular dilatation, but in the majority of patients no identifiable cause is found-hence the term "idiopathic" dilated cardiomyopathy (IDC) . There are experimental and clinical data in animals and humans suggesting that genetic, viral, and immune factors contribute to the pathophysiology of IDC.
Diagnosis

Clinical presentation
The first presentation of IDC may be with systemic embolism or sudden death, but patients more typically present with signs and symptoms of pulmonary congestion and/or low cardiac output, often on a background of exertional symptoms and fatigue for many months or years before their diagnosis. Intercurrent illness or the development of arrhythmia, in particular atrial fibrillation, may precipitate acute decompensation in such individuals. Increasingly, IDC is diagnosed incidentally in asymptomatic individuals during routine medical screening or family evaluation of patients with established diagnosis.
A careful family history facilitates diagnosis of inherited causes of IDC by characterising the family phenotype, and also defines the scope of family screening.
1 At least 25% of patients have evidence for familial disease with predominantly autosomal dominant inheritance. Clinically, familial disease is defined by the presence of two or more aVected individuals in a single family and should also be suspected in all patients with IDC and a family history of premature cardiac death or conduction system disease. A further 20% of relatives have isolated left ventricular enlargement that can progress to IDC in a minority of cases. Dilated cardiomyopathy can occur in a number of X linked diseases such as Becker's and Duchenne's muscular dystrophies and X linked IDC. It may also occur in patients with mitochondrial DNA mutations and inherited metabolic disorders. Thus when taking a family history, specific attention should be given to a history of muscular dystrophy, features of mitochondrial disease (for example, familial diabetes, deafness, epilepsy, maternal inheritance), and signs and symptoms of other inherited metabolic diseases. Inborn errors of metabolism usually present in infancy and childhood, but some may present in adulthood, in particular haemochromatosis. Nutritional deficiencies and endocrine abnormalities may produce heart failure, and a complete drug history is essential, both in relation to the administration of cardiotoxic drugs such as anthracyclines and with respect to the use of illegal substances. Cocaine abuse, in particular, can produce a chronic IDC picture as well as an acute cardiomyopathy. Exposure to HIV and other infectious agents such as hepatitis C may be relevant in some patients. 
CARDIOMYOPATHY
Endomyocardial biopsy
Although endomyocardial biopsy can be used to diagnose a wide range of myocardial diseases, most are rare causes of IDC and can often be diagnosed by other means. Even the detection of an inflammatory cardiomyopathy is of limited use, given the uncertainties and inconsistencies surrounding its diagnosis using conventional light microscope criteria. Endomyocardial biopsy may be of use in selected patients-for example, those with suspected cardiac haemochromatosis and other infiltrative or malignant diseases-but in general it should be confined to carefully conducted clinical trials. A number of immunohistological studies have already demonstrated increased numbers of T cells and increased expression of endothelial and interstitial MHC (major histoDiagnostic criteria for IDC Ejection fraction < 0.45 and/or a fractional shortening of < 25%, and a left ventricular end diastolic dimension of > 112% predicted value corrected for age and body surface area.
Exclusion criteria:
x Absence of systemic hypertension (> 160/100 mm Hg)
x Coronary artery disease (> 50% in one or more major branches)
x Chronic excess alcohol (> 40 g/day female, > 80 g/day male for more than five years after six month abstinence
x Systemic disease known to cause IDC
x Pericardial diseases
x Congenital heart disease x Cor pulmonale
Key
The criteria for left ventricular enlargement are based on data of Henry et al (Circulation 1980; 62:1054-61) . A value of > 112% of predicted represents 2 SDs from the mean corrected for body surface area and age given by the formula: (45.3 × (body surface area) 1/3 − (0.03 × age) − 7.2) ±12%. Mestroni et al have suggested a more conservative cut oV of > 117% (2 SDs + 5%) in order to increase specificity for family studies. However, a value of 112% is probably just as predictive of disease if systolic function is also abnormal.
Education in Heart compatibility complex) antigens and cell adhesion molecules in IDC hearts, consistent with previous observations of immune activity in IDC (fig 2) . 3 As our understanding of the clinical significance of immunohistochemical markers improves, it is likely that endomyocardial biopsy will become more important in guiding immunomodulatory treatment.
Treatment
Specific treatments are not available for most patients with IDC. Therefore, the primary aims of treatment are to control symptoms and to prevent disease progression and complications such as progressive heart failure, sudden death, and thromboembolism. Diuretics remain central to the management of congestive symptoms, but they should not be used as monotherapy as they exacerbate neurohumoral activation and may contribute to disease progression unless administered concomitantly with neurohumoral antagonists. ANGIOTENSIN CONVERTING ENZYME INHIBITORS Activation of the renin-angiotensinaldosterone system (RAAS) is central to the pathophysiology of heart failure of whatever underlying aetiology. For this reason, angiotensin converting enzyme (ACE) inhibitors are the mainstays of treatment in patients with IDC, irrespective of the severity of heart failure.
4 ACE inhibitors improve dyspnoea and exercise tolerance, reduce hospitalisation rates, and reduce cardiovascular mortality. They also 
Recommended tests in adult patients
with IDC
x Erythrocyte sedimentation rate (ESR)
x Creatine kinase (CK)
x Viral serology (if acute presentation)
x Renal function
x Liver function tests/calcium
x Serum ferritin/iron/transferrin
x Thyroid function tests
Only in specific indications:
x Coronary angiography
x Blood -autoantibodies -carnitine -lactate/pyruvate -selenium -pyruvate -acylcarnitine profile -drug screen -red cell transketolase (beri beri) -infective screen (HIV/hepatitis C, enteroviruses)
x Urine -organic acid/amino acids x Skeletal muscle biopsy
x Endomyocardial biopsy Education in Heart prevent or slow disease progression in asymptomatic patients. A substantial proportion of patients who are given ACE inhibitors fail to reach the target doses reported in randomised studies. Recent evidence from the ATLAS study 5 suggests that maximum recommended doses of lisinopril (32.5-35 mg) are as well tolerated as low doses (2.5-5 mg), and are associated with a 12% greater reduction in the combined risk of death or hospitalisation. Although the comparative benefit of intermediate doses is still uncertain, it seems prudent to try to achieve recommended target doses in most patients.
Significant side eVects are uncommon during ACE inhibitor treatment, the most frequent being hypotension, cough, and deterioration of renal function. Mild impairment of renal function (creatinine up to 265 µmol/l) in the absence of renal artery stenosis is not, however, an absolute contraindication for ACE inhibition. Similarly, a resting systolic pressure of 80-90 mm Hg during treatment is acceptable in the absence of postural symptoms. When side eVects are problematic, the first step is to consider reducing the dose of other medications. In particular, diuretic doses can often be reduced in patients who no longer have congestive symptoms. When ACE inhibitors have to be discontinued, hydralazine-nitrate combination can be useful in treating congestive symptoms.
ANGIOTENSIN II RECEPTOR ANTAGONISTS Angiotensin II (AII) receptor antagonists have recently attracted much interest and controversy with regard to their place in the heart failure therapeutic armoury. AII receptor antagonists have haemodynamic eVects broadly similar to those of ACE inhibitors, but may be slightly better tolerated and at least theoretically overcome the "escape" of angiotensin system blockade observed in some patients on ACE inhibitors. However, unlike ACE inhibitors, AII receptor antagonists do not inhibit bradykinin metabolism and thus lack a potentially beneficial vasodilatory eVect. The ELITE-1 study 6 suggested that losartan may have a greater eVect on mortality than captopril in elderly patients with mild to moderate heart failure. Preliminary data from the follow up to this study have failed to demonstrate a superior eVect of losartan over captopril, but the study was not powered to detect equivalence between the two drugs. The recent RESOLVD study 7 has suggested that combination treatment with an ACE inhibitor and an AII antagonist may be more beneficial in reducing neurohumoral activation and in preventing ventricular remodelling than either drug alone. A number of trials (VALHEFT, CHARM) are currently addressing these and other issues regarding AII receptor treatment.
BLOCKERS
In spite of ACE inhibitor treatment, mortality continues to be high in patients with heart failure. This is perhaps not surprising given that ACE inhibitors act on only one aspect of the neurohumoral cascade (RAAS) that contributes to progressive left ventricular dysfunction. It has been recognised for some time that excess sympathetic activity contributes to the clinical syndrome of heart failure, but it was only recently that use of blockers in heart failure patients gained widespread acceptance. Three recent multicentre placebo controlled studies, the US carvedilol studies, 8 CIBIS II (bisoprolol), 9 and MERIT-HF (metoprolol), 10 have demonstrated substantial reductions in sudden death and death from progressive heart failure in patients with predominantly New York Heart Association (NYHA) class II and III symptoms treated with blockers. In CIBIS II and MERIT-HF, but not the US carvedilol study, subgroup analysis suggested a greater eVect in patients with ischaemic heart failure compared to "non-ischaemic" heart failure. Nevertheless, when taken together with earlier studies, these data suggest that it is advisable to consider blockers in IDC patients with mild to moderate symptoms in spite of maximal treatment with ACE inhibitors. Patients should not be started on blockers if they have signs or symptoms of decompensated heart failure, and initial doses should be low (carvedilol 3.125 mg twice daily, bisoprolol 1.25 mg once daily, metoprolol SR 12.5 mg once daily). Doses should be increased gradually every 2-4 weeks, monitoring closely for hypotension, bradycardia or worsening heart failure until the target dose is achieved or side eVects occur.
SPIRONOLACTONE
High plasma concentrations of aldosterone are frequent in patients with moderate to severe heart failure and contribute to sodium retention, potassium loss, sympathetic activation, myocardial fibrosis, and baroreceptor dysfunction. ACE inhibition usually results in only a transient decrease in aldosterone concentrations, probably because a major source of aldosterone is reduced hepatic clearance rather than angiotensin dependent adrenal secretion. The recent RALES study 11 has shown that the addition of 25 mg of spironolactone to conventional treatment in patients with an ejection fraction < 35% and a history of NYHA class IV heart failure is associated with a 30% reduction in the overall risk of death. Hospitalisation rates for cardiac causes and functional status also improved, and serious hyperkalaemia was infrequent in patients with a serum creatinine < 221 µmol/l. The drug should be considered in all patients presenting with moderate to severe heart failure symptoms.
Novel potential pharmacological treatments
NATRIURETIC PEPTIDES Atrial natriuretic peptide (ANP) is released from atrial myocytes in response to stretch, and induces diuresis, naturesis, vasodilatation, and suppression of the renin-angiotensin system. Circulating concentrations of ANP are increased in congestive cardiac failure and correlate with NYHA functional class and progno-sis. Both ANP and brain natriuretic peptide are potent vasodilators and diuretics, but clinical trials have shown that tolerance frequently develops during intravenous ANP administration. This problem may be overcome by the development of drugs that inhibit neutral endopeptidase, the enzyme responsible for breakdown of natriuretic peptides. CYTOKINE ANTAGONISTS Tumour necrosis factor (TNF ) or cachectin is a proinflammatory cytokine released from activated macrophages, T cells, and failing myocardium. It circulates at high concentrations in patients with congestive cardiac failure and in experimental models causes pulmonary oedema, cardiomyopathy, cachexia, and reduced peripheral blood flow. Raised plasma concentrations of TNF and other proinflammatory cytokines such as interleukin 6 have been interpreted as epiphenomena of heart failure, but it is increasingly thought that cytokines may promote heart failure progression. The experience with TNF antagonists in heart failure is limited, but there are intriguing data on pentoxyfilline, a xanthine derivative that suppresses TNF production, 12 and etanercept, a soluble P75 tumour necrosis factor receptor that binds irreversibly with TNF .
13 Etanercept is currently being evaluated in two large multicentre studies (RENAISSANCE and RECOVER).
Endothelins are another family of locally acting peptides with profound vasoconstrictor eVects found in high plasma concentrations in patients with heart failure. Experimental data using the endothelin antagonist bosentan have shown favourable haemodynamic eVects in heart failure patients, although the drug is associated with dose related hepatic dysfunction, prompting the investigation of more selective endothelin antagonists.
ANTICOAGULANTS
Although the annual risk of thromboembolism in patients with IDC is relatively low, many patients are young and are exposed to an appreciable cumulative risk of systemic embolisation. At present there are no trial data to guide anticoagulant treatment in IDC, but warfarin is advised in patients with a history of thromboembolism or evidence of intracardiac thrombus. Patients with more than moderate ventricular dilatation and moderate to severe systolic dysfunction should also be advised to take warfarin.
Management of arrhythmia in IDC
There are substantial limitations to most currently available antiarrhythmic drugs in IDC, in particular their negative inotropic and proarrhythmic eVects. Evidence from studies showing increased mortality in patients with advanced heart failure treated with class I agents suggest that these drugs should not be used to prevent arrhythmias of any origin in IDC except in an emergency. Two large scale trials have evaluated amiodarone in IDC, but only one, GESICA, 14 has demonstrated an improvement in overall prognosis. The second study, CHF-STAT, 15 did not demonstrate an improvement in overall survival, but there was a non-significant trend towards improved survival in patients with "non-ischaemic" cardiomyopathy. Dofetilide, 16 a more recently developed class III agent, has a neutral eVect on overall survival but does reduce the incidence of atrial fibrillation. These data suggest that class III agents can be safely used to treat or prevent symptomatic supraventricular arrhythmias in IDC, but they cannot be recommended for sudden death prophylaxis. There are as yet no large scale randomised data of implantable cardioverter defribrillator (ICD) treatment in IDC, but it is reasonable to consider ICDs in patients with sustained haemodynamically unstable ventricular tachycardia/fibrillation. The role of ICDs in patients without symptomatic ventricular arrhythmia will hopefully be answered by ongoing trials (for example, SCD-HEFT).
Non-pharmacological treatment of advanced heart failure
Heterotopic heart transplantation is still the cornerstone of advanced heart failure management in patients with intractable heart failure symptoms and end stage disease. However, transplantation remains limited by the scarcity of suitable organs and the development of graft vasculopathy. In response to this dilemma several novel approaches are being evaluated.
Partial left ventriculectomy is based on the hypothesis that as wall tension is related to left ventricular diameter (Laplace's law), reducing the left ventricular size by excision of a portion of its circumference should reduce wall stress and improve ventricular haemodynamics. In the best centres results from this intervention were initially remarkably good given the nature of the procedure. It is clear, however, that even with careful patient selection many patients survive only with the benefit of left ventricular assist devices and subsequent transplantation.
17
Late sudden death is also described in a proportion of survivors. The diYculties associated with patient selection and subsequent postoperative care suggest that, at best, this form of treatment will be confined to a very small number of experienced centres.
LEFT VENTRICULAR ASSIST DEVICES Left ventricular assist devices (LVADs) have recently received approval from the US Food and Drug Administration for use in patients with end stage heart failure as a bridge to cardiac transplantation. Experience in patients with IDC suggests that LVAD treatment can result in an apparent improvement in left ventricular function that may persist when the device is removed. However, there are as yet no reliable markers that distinguish the minority of patients that sustain useful recovery from the majority that deteriorate following explantation of the device. Technical advances in LVAD design now raise the possibility of using these devices as an alternative to transplantation in patients who are not transplant candidates. This mode of treatment is currently being evaluated in the REMATCH study, 18 which if positive will have substantial clinical and resource implications for centres managing advanced heart failure.
MULTISITE VENTRICULAR PACING Many patients with advanced IDC have abnormal left ventricular activation that in turn results in prolonged and incoordinate ventricular relaxation. In some patients ventricular conduction delay is also associated with prolongation of atrioventricular conduction, resulting in a loss of atrioventricular synchrony and a predisposition to prolonged functional mitral regurgitation. Dual chamber pacing has been advocated as a method for restoring AV synchrony and improving left ventricular coordination in patients with severe congestive heart failure. Although initially favourable haemodynamic results using conventional right ventricular pacing were not confirmed by later studies, there has been a more consistent response in studies that have used biventricular pacing, the outcome depending critically on the native QRS duration and the paced AV delay. 19 Patients should be considered for biventricular pacing if they have QRS duration greater than 150 ms, PR interval prolongation, and symptoms refractory to conventional medical treatment.
Immunomodulation/immunosuppression
While there is considerable evidence to suggest that autoimmunity plays a significant role in the pathophysiology of IDC, there has been little evidence to suggest that immunosuppressive treatment is of any benefit. This lack of response is, perhaps, not that surprising given the limitations of criteria used to select patients for treatment in immunosuppresive studies and the heterogeneity of the underlying aetiology of the condition. Immunosuppression is also a rather indiscriminate weapon, as it may suppress potentially beneficial immune responses such as neutralising antibody production in patients with chronic viral myocarditis. New approaches to the diagnosis of chronic myocarditis and the treatment of inflammatory cardiomyopathy should improve this situation. There are already interesting preliminary data suggesting that high dose immunoglobulin 20 and immunoadsorption may result in short term improvement in left ventricular performance in patients with dilated and peripartum cardiomyopathy.
The future
IDC is a disease of diverse causes and pathophysiology. Among the many challenges facing clinicians treating patients with the disorder are the detection of early disease, the identification of the predominant mechanism of left ventricular dysfunction, and the development of treatments that target the initiating mechanism of disease. Nevertheless, there have been major advances in our understanding of the genetic and immunological basis of IDC, and recent advances in the pharmacotherapy of heart failure have substantially improved the outlook for many patients. The rapid pace of current research and the development of new treatments for the management of both early and late disease augur well for the future. • The inherited nature of IDC is often overlooked in the management of patients with IDC. This paper provides a set of practical guidelines for the clinical diagnosis of gene carriers.
2. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart 1997;78:539-43.
• This review discusses some of the potential reasons for the wide range of estimates for viral infection in patients with IDC. In many cases methodological considerations are just as important as genuine variation in the incidence of viral infection. 
